Which agent is an IL-12/23 inhibitor used in psoriatic arthritis?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $24.99Unlock all

Prepare for the CMS II Rheumatology E1 Exam with our comprehensive quiz. Study using flashcards and multiple-choice questions, each with hints and explanations. Get ready for success!

Multiple Choice

Which agent is an IL-12/23 inhibitor used in psoriatic arthritis?

Explanation:
Understanding IL-12/23 inhibitors requires recognizing that IL-12 and IL-23 share a common p40 subunit. Ustekinumab is a monoclonal antibody that targets this p40 subunit, blocking both IL-12 and IL-23 signaling. By inhibiting these pathways, it reduces the activity of Th1 and Th17 cells, which are drivers of inflammation in psoriasis and psoriatic arthritis. That makes ustekinumab effective as an IL-12/23 inhibitor in psoriatic arthritis. In contrast, the other agents target IL-17A or the IL-17 receptor rather than IL-12/23, so they do not belong to the IL-12/23 inhibitor class.

Understanding IL-12/23 inhibitors requires recognizing that IL-12 and IL-23 share a common p40 subunit. Ustekinumab is a monoclonal antibody that targets this p40 subunit, blocking both IL-12 and IL-23 signaling. By inhibiting these pathways, it reduces the activity of Th1 and Th17 cells, which are drivers of inflammation in psoriasis and psoriatic arthritis. That makes ustekinumab effective as an IL-12/23 inhibitor in psoriatic arthritis.

In contrast, the other agents target IL-17A or the IL-17 receptor rather than IL-12/23, so they do not belong to the IL-12/23 inhibitor class.

More Multiple Choice Questions
Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy